Medigen Vaccine Biologics Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-281.71	-80.47	-1,160	-1,475	1,410
Depreciation & Amortization	140.46	134.99	130	127.26	112.33
Other Amortization	1.33	1.45	1.17	0.63	0.22
Loss (Gain) From Sale of Assets	9.2	-0.41	-	-	-
Loss (Gain) From Sale of Investments	-	-1.42	9.64	16.55	0.07
Stock-Based Compensation	31.01	14.16	18.31	75.61	68.82
Other Operating Activities	-3.34	71.32	-16.66	19.32	-0.02
Change in Accounts Receivable	-11.99	31.08	45.29	445.79	-635.73
Change in Inventory	58.31	-68.43	161.15	18.71	-486.06
Change in Accounts Payable	-2.79	-12.5	-82.64	21.72	65.63
Change in Unearned Revenue	-	-	-	-111.41	111.41
Change in Other Net Operating Assets	10.45	-49.03	411.02	-353.41	-67.03
Operating Cash Flow	-49.09	40.75	-482.56	-1,214	579.89
Capital Expenditures	-50.64	-34.3	-38.69	-139.17	-133.63
Sale of Property, Plant & Equipment	3.29	0.87	-	-	120
Sale (Purchase) of Intangibles	-1.14	-0.68	-2.27	-1.17	-1.34
Investment in Securities	20	1,050	636.38	-2,279	-881.8
Other Investing Activities	-6.81	1.29	74.4	134.74	-33.93
Investing Cash Flow	-35.3	1,018	669.83	-2,285	-930.69
Short-Term Debt Issued	-	-	-	-	30
Long-Term Debt Issued	-	-	-	1,755	-
Total Debt Issued	-	-	-	1,755	30
Short-Term Debt Repaid	-	-	-	-	-30
Long-Term Debt Repaid	-39.19	-1,740	-11.78	-11.56	-1.93
Total Debt Repaid	-39.19	-1,740	-11.78	-11.56	-31.93
Net Debt Issued (Repaid)	-39.19	-1,740	-11.78	1,744	-1.93
Issuance of Common Stock	-	3.47	13.37	1,579	55.68
Other Financing Activities	-	-	-	-	-2.58
Financing Cash Flow	-39.19	-1,736	1.59	3,323	51.18
Foreign Exchange Rate Adjustments	-	0.11	0	0.35	-0.11
Net Cash Flow	-123.58	-677.51	188.87	-175.44	-299.73
Free Cash Flow	-99.72	6.46	-521.25	-1,353	446.26
Free Cash Flow Margin	-16.26%	1.07%	-133.78%	-370.64%	13.60%
Free Cash Flow Per Share	-0.30	0.02	-1.59	-4.18	1.39
Cash Interest Paid	8.66	7.72	7.32	7.53	6.02
Levered Free Cash Flow	-3.72	-81.08	-164.31	-744.24	-288.35
Unlevered Free Cash Flow	1.79	-69.27	-140.83	-727.43	-284.59
Change in Working Capital	53.98	-98.88	534.82	21.39	-1,012

Source: S&P Global Market Intelligence. Standard template. Financial Sources.